WHO Monitors New Covid Variant Spreading in America and Europe

NB.1.8.1 has mutations that could increase the virus’s transmissibility and decrease the efficacy of certain neutralizing antibodies against it.

A new Covid variant is being kept under surveillance by the World Health Organization (WHO) as its emergence has led to an increase in infections in several regions of the world. First identified at the end of January, the variant—called NB.1.8.1 but known informally as “Nimbus”—is a descendant of the Omicron family of Covid sublineages, and has become increasingly prevalent throughout the spring in Europe, the Americas, and the Western Pacific.

The virus has mutations that may increase its infectiousness and allow it to escape certain antibodies. Nevertheless, “considering the available evidence, the additional public health risk posed by NB.1.8.1 is evaluated as low at the global level,” the WHO wrote in its most recent risk evaluation for the variant.

Like other variants before it, Nimbus has specific mutations to its spike protein. These proteins coat the virus’s surface and are what it uses to gain entry into cells, where it reproduces. Nimbus’ spike protein modifications could increase its transmission capacity and partially reduce the neutralizing efficacy of certain antibodies generated by previous infections, both of which would contribute to its spread.

However, the WHO says that there is no evidence that this variant causes more severe disease compared to other strains currently circulating. Nor have increases in hospitalizations or deaths related to its emergence been observed.

Symptoms associated with NB.1.8.1 are similar to those caused by other SARS-CoV-2 variants: sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, and diarrhea.

The WHO experts explain that, although this variant may partially evade some antibody responses, such “immune escape” is comparable to that observed in other Omicron sublineages. This suggests that the mutations present in NB.1.8.1 do not give the virus increased resistance to antivirals such as nirmatrelvir, and that current vaccines continue to be effective in preventing severe disease when infected with this version of the virus.

However, to those most vulnerable to Covid—such as the elderly, immunocompromised, or those with preexisting chronic conditions—Nimbus represents a new health threat, and these groups should stay up to date with booster vaccinations to ensure they are protected against Covid’s worst effects.

This story originally appeared on WIRED en Español and has been translated from Spanish.

Source

Hope you enjoyed this news post.

Thank you for appreciating my time and effort posting news every day for many years.

News posts... 2023: 5,800+ | 2024: 5,700+ | 2025 (till end of May): 2,377

RIP Matrix | Farewell my friend